Key result
Colchicine daily reduced major cardiovascular events in COLCOT and LoDoCo2, but showed no benefit in the largest trial CLEAR.
Why the study?
Patients with coronary artery disease remain at risk of recurrent cardiovascular events despite standard therapy, prompting evaluation of the efficacy and safety of low-dose colchicine across large randomized controlled trials for secondary prevention.
Does low-dose colchicine (0.5 mg daily) reduce the composite of major cardiovascular events in adults with coronary artery disease or recent myocardial infarction compared to placebo?
Systematic Review (n=17,329)
Double-blind (COLCOT) and placebo-controlled (LoDoCo2, CLEAR)
Placebo-controlled randomized controlled trials (COLCOT, LoDoCo2, CLEAR; CLEAR also used a 2x2 factorial design)
Yes
Does low-dose colchicine (0.5 mg daily) reduce the composite of major cardiovascular events in adults with coronary artery disease or recent myocardial infarction compared to placebo?
Because two large RCTs showed cardiovascular benefit with low-dose colchicine while the largest trial (CLEAR) showed no benefit and increased diarrhea, the current evidence is inconsistent and does not support routine use for secondary prevention in coronary artery disease.
Answers are grounded in this paper and cite their sources.
Inconsistent trial results do not support routine low-dose colchicine for CAD secondary prevention; challenges prior positive RCTs and leaves efficacy open.
Background: Patients with coronary artery disease remain at risk of recurrent cardiovascular events despite standard therapy. Low-dose colchicine, an anti-inflammatory drug, has been tested in large randomized controlled trials (RCTs). This systematic review summarizes its efficacy and safety for secondary prevention. Methods: Placebo-controlled RCTs of low-dose colchicine in adults with coronary artery disease or recent myocardial infarction, reporting a composite of major cardiovascular events, were eligible. Data were extracted and synthesized without meta-analysis following the SWiM reporting guideline, with qualitative risk-of-bias appraisal using RoB 2 domains. Findings: Three RCTs (COLCOT, LoDoCo2, CLEAR; 17,329 randomized participants) were included. Colchicine 0.5 mg reduced the primary composite outcome in COLCOT (HR 0.77, 95% CI 0.61–0.96) and LoDoCo2 (HR 0.69, 95% CI 0.57–0.83), but not in CLEAR (HR 0.99, 95% CI 0.85–1.16). Diarrhea was more frequent with colchicine in CLEAR (10.2% vs 6.6%), serious pneumonia was more frequent in COLCOT (0.9% vs 0.4%), and non-cardiovascular death was numerically higher in LoDoCo2 (HR 1.51, 95% CI 0.99–2.31). Conclusion: Evidence for colchicine in secondary prevention is inconsistent: two trials showed benefit and the largest trial showed none. Routine use cannot be supported on this evidence alone.
No takes yet. Share an insight, caveat, or question.
Masri et al. (2026) conducted a systematic review in Coronary artery disease or recent myocardial infarction (n=17,329). Low-dose colchicine vs. Placebo was evaluated on Composite of major cardiovascular events (synthesized without meta-analysis across 3 RCTs; no pooled estimate calculated). Colchicine daily reduced major cardiovascular events in COLCOT and LoDoCo2, but showed no benefit in the largest trial CLEAR.
Synapse has enriched 10 related papers. Consider them for comparative context: